You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK)附屬公佈西達基奧侖賽1b/2期合併CARTITUDE-1研究最新資料
格隆匯 12-06 18:52

格隆匯 12 月 6日丨金斯瑞生物科技(01548.HK)發佈公告,公司非全資附屬公司傳奇生物科技股份有限公司於2020年12月5日(紐約時間)公佈西達基奧侖賽(cilta-cel) 的1b/2期合併CARTITUDE-1研究(NCT03548207)的最新資料。該研究結果顯示了持續較高的總緩解率(ORR),ORR隨着時間延長不斷加深。中位隨訪時間12.4個月時,97%患者獲得緩解,67%患者獲得嚴格的完全緩解(sCR)。該資料在第62屆美國血液學會(ASH)年會和展覽會上進行了口頭報導(Abstract #177)。

西達基奧侖賽是一種在研的靶向B細胞成熟抗原(BCMA)嵌合抗原受體T細胞(CAR-T)療法,用於治療復發或難治性多發性骨髓瘤(RRMM)患者,該療法由Janssen Research & Development, LLC申報。

CARTITUDE-1研究強有力的結果使集團很受鼓舞,這顯示了其主要研發產品西達基奧侖賽有潛力成為復發或難治性多發性骨髓瘤患者的變革性治療選擇。集團期待為有需求的患者推進這種可能挽救生命的治療方法。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account